To include your compound in the COVID-19 Resource Center, submit it here.

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

Actavis plc (NYSE:ACT) gained $3.09 to $234.38 last week after FDA's Cardiovascular and Renal Drugs Advisory Committee voted 6-4 against approval of an NDA for a fixed-dose combination of nebivolol and valsartan to treat hypertension. The product has a Dec. 24 PDUFA date.

Amarin Corp. plc (NASDAQ:AMRN) fell $0.32 (18%) $1.49 on Friday after FDA's Office of New Drugs denied the company's appeal seeking to reinstate an SPA for the Phase III ANCHOR trial of Vascepa icosapent ethyl. The trial was evaluating Vascepa in combination with statins to treat high triglycerides in patients with mixed dyslipidemia, an indication Amarin is seeking to add to Vascepa's label. FDA revoked the SPA last year. Amarin said it is evaluating OND's response and has

Read the full 1203 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers